May 16, 2018 / 9:16 PM / 2 months ago

BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination Regimens

May 16 (Reuters) - ImmunoGen Inc:

* IMMUNOGEN ANNOUNCES POSITIVE FINDINGS FROM THE FORWARD II STUDY OF MIRVETUXIMAB SORAVTANSINE COMBINATION REGIMENS WITH AVASTIN® AND CARBOPLATIN IN OVARIAN CANCER

* IMMUNOGEN - UPDATED DATA FROM CARBOPLATIN DOSE-ESCALATION COHORT DEMONSTRATE INCREASED RESPONSE RATE AND DURABLE BENEFIT WITH LONGER-TERM FOLLOW UP Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below